imatinib mesylate has been researched along with Renal Insufficiency in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Du, J; Fan, X; Kong, X; Li, A; Liang, L; Lin, L; Song, J | 1 |
| Hino, A; Ishikawa, J; Koike, M; Masaie, H; Minami, R; Tada, Y; Yoshida, H | 1 |
| Hohl, RJ; Holstein, SA; Stokes, JB | 1 |
| Kansu, E; Koc, Y; Ozdemir, E | 1 |
| Cobanoglu, U; Omay, SB; Ovali, E; Sonmez, M | 1 |
| Atichartakarn, V; Kitiyakara, C | 1 |
6 other study(ies) available for imatinib mesylate and Renal Insufficiency
| Article | Year |
|---|---|
Treatment with imatinib was useful to delay the neointimal hyperplasia of aortocaval fistula in adenine-induced renal failure rats.
Topics: Animals; Constriction, Pathologic; Fistula; Hyperplasia; Imatinib Mesylate; Neointima; Proto-Oncogene Proteins c-kit; Rats; Renal Insufficiency | 2023 |
Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Creatine; Dasatinib; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Renal Insufficiency | 2016 |
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles | 2009 |
Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Renal Dialysis; Renal Insufficiency; Treatment Outcome | 2006 |
Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Insufficiency; Thiazoles | 2008 |
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Renal Insufficiency | 2002 |